Results 51 to 60 of about 399,367 (396)

Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis [PDF]

, 2010
Background A substantial number of epidemiologic studies have provided estimates of the relation between exposure to benzene at work and the risk of leukemia, but the results have been heterogeneous.
A Le Noir, Abdul Khalade, AC Capleton, AR Schnatter, AR Schnatter, AS Costantini, AS Costantini, B Ireland, B Jarvholm, D Consonni, DA Savitz, DB Petitti, DB Richardson, DC Glass, Eero Pukkala, J Kirkeleit, JJ Collins, Jouni JK Jaakkola, L Rushton, LJ Bloemen, M Borenstein, Maritta S Jaakkola, RA Rinsky, RB Hayes, SH Lamm, T Sorahan, T Sorahan   +26 more
core   +4 more sources

Autoimmune Hemolytic Anemia After Relapse of Chronic Myeloid Leukemia: A Case Report

Clinical Medicine Insights: Blood Disorders, 2019
Autoimmune hemolytic anemia is one of the differential diagnoses for anemia in patients with lymphoproliferative neoplasia, such as chronic lymphocytic leukemia, who experience sudden drop in hemoglobin.
Tahseen Hamamyh, Mohamed A Yassin
doaj   +1 more source

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Journal of Clinical Oncology, 2016
PURPOSE A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI).
H. Bower, M. Björkholm, P. Dickman, M. Höglund, P. Lambert, T. Andersson   +5 more
semanticscholar   +1 more source

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment [PDF]

, 2009
Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Henschler, Reinhard, Moore, Malcolm A. S., Oancea, Claudia, Ruthardt, Martin, Zheng, Xiaomin   +4 more
core   +3 more sources

Radiation-induced myeloid leukemia in murine models. [PDF]

, 2014
The use of radiation therapy is a cornerstone of modern cancer treatment. The number of patients that undergo radiation as a part of their therapy regimen is only increasing every year, but this does not come without cost.
Davoren, Michael, Rivina, Leena, Schiestl, Robert H   +2 more
core   +2 more sources

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature

Indian Journal of Pathology and Microbiology, 2013
Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar, Jasmina Ahluwalia, Pankaj Malhotra, Man Updesh Singh Sachdeva   +3 more
doaj   +1 more source

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

New England Journal of Medicine, 2019
BACKGROUND Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib targets both native
T. Hughes, M. Mauro, J. Cortes, H. Minami, D. Réa, D. DeAngelo, M. Breccia, Y. Goh, M. Talpaz, A. Hochhaus, P. le Coutre, O. Ottmann, M. Heinrich, J. Steegmann, M. Deininger, J. Janssen, F. Mahon, Y. Minami, D. Yeung, D. Ross, M. Tallman, Jae H. Park, B. Druker, David Hynds, Yuyan Duan, C. Meille, F. Hourcade‐Potelleret, K. G. Vanasse, F. Lang, Dong-Wook Kim   +29 more
semanticscholar   +1 more source

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Chronic myeloid leukemia stem cells

Leukemia, 2019
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC).
M. Houshmand, G. Simonetti, P. Circosta, V. Gaidano, A. Cignetti, G. Martinelli, G. Saglio, R. Gale   +7 more
semanticscholar   +1 more source

Chronic myeloid leukemia in Asia

International Journal of Hematology, 2008
Chronic myeloid leukemia (CML) in Asia has an incidence rather lower than in Western countries yet tends to afflict a younger population. As in the West, imatinib mesylate (IM, Glivec) has supplanted busulphan, hydroxyurea and interferon-alpha as first-line treatment.
Jootar, S, Kim, DW, O'Neil, WM, Caguioa, PB, Kweon, IY, Hsu, SC, Chuah, C, Saikia, TK, Au, WY, Wang, J   +9 more
openaire   +4 more sources